Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-07-16 20:05:50 ET · period of report 2026-07-14 · accession 0001553350-26-000111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-16 20:05 | 2026-07-14 | STLN | Podnos Yale | Chief Medical Off | M - OptEx | $1.90 | +23.5K | 265.0K | +10% | +$44.6K |
| DMT | 2026-07-16 20:05 | 2026-07-14 | STLN | Podnos Yale | Chief Medical Off | S - Sale+OE | $6.41 | -23.5K | 259.5K | -8% | -$150.3K |
| DMT | 2026-07-16 20:05 | 2026-07-14 | STLN | Podnos Yale | Chief Medical Off | M - OptEx | $1.90 | +23.5K | 0 | New | +$44.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-14 | M | A | 17,974 | $1.87 | 277,501 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-14 | S | D | 17,974 | $6.43 | 259,527 | D | — | — | (F1) The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025. (F3) The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1. |
| 3 | Common | Common Stock | 2026-07-14 | M | A | 5,478 | $2.00 | 265,005 | D | — | — | |
| 4 | Common | Common Stock | 2026-07-14 | S | D | 5,478 | $6.35 | 259,527 | D | — | — | (F1) The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025. (F3) The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-07-14 | M | A | 17,974 | $1.87 | 0 | D | $1.87 · — to 2032-11-17 | 17,974 Common Stock | (F2) The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-07-14 | M | A | 5,478 | $2.00 | 0 | D | $2.00 · — to 2034-05-21 | 5,478 Common Stock | (F2) The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms. |